Iterum Therapeutics plc (ITRMF)
| Market Cap | 528.00 -100.0% |
| Revenue (ttm) | 390.00K |
| Net Income | -26.96M |
| EPS | -0.74 |
| Shares Out | 52.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,016 |
| Open | n/a |
| Previous Close | 0.0001 |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 3.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About Iterum Therapeutics
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous... [Read more]
Financial Performance
Financial StatementsNews
Iterum files wind-up petition due to limited cash, inability to raise equity
Iterum Therapeutics said on Friday it has filed a petition in Ireland's High Court to wind up the drugmaker and was placed into provisional liquidation, with a hearing set for April 13.
Iterum Therapeutics Announces Filing of Winding Up Petition
DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next gen...
Iterum Therapeutics Provides Business Update
--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Thera...
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on February 13, 2026, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on January 26, 2026, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Slides: Investor presentation
Iterum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 20, 2026.
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on January 2, 2026, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on December 23, 2025, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Slides: Investor Presentation
Iterum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 17, 2025.
Iterum Therapeutics Earnings Call Transcript: Q3 2025
Orlynvah’s U.S. launch generated $0.4M in Q3 sales, with over 280 prescriptions and growing physician adoption. 2026 revenue is guided at $5–$15M, but further capital is needed to sustain commercialization beyond Q2 2026. Coverage now reaches 16% of insured lives.
Iterum Therapeutics Quarterly report: Q3 2025
Iterum Therapeutics has published its Q3 2025 quarterly earnings report on November 14, 2025.
Iterum Therapeutics Earnings release: Q3 2025
Iterum Therapeutics released its Q3 2025 earnings on November 14, 2025, summarizing the period's financial results.
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
- -Commercially Launched ORLYNVAH ™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. ...
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infect...
Iterum Therapeutics to Present Data at IDWeek 2025
DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections ...
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections FDA-approved antibiotic with the power of...
Iterum Therapeutics Earnings Call Transcript: Q2 2025
ORLYNVAH is launching ahead of schedule in a large, underserved U.S. market, with initial sales targeting high-value territories and strong patent protection. Q2 2025 saw increased expenses due to pre-commercialization, but cash is expected to fund operations into 2026.
Iterum Therapeutics Quarterly report: Q2 2025
Iterum Therapeutics has published its Q2 2025 quarterly earnings report on August 5, 2025.
Iterum Therapeutics Earnings release: Q2 2025
Iterum Therapeutics released its Q2 2025 earnings on August 5, 2025, summarizing the period's financial results.
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
- - Launch of ORLYNVAH TM Expected August 2025— - -Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeuti...
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infect...
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on July 29, 2025, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Proxy statement: Proxy Filing
Iterum Therapeutics filed a proxy statement on July 18, 2025, providing details for shareholder voting and corporate governance matters.
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to a...
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to a...